Mercedes-Benz Group Shares Fall on Third-Quarter Profit Drop

1 Mins read

Shares of Mercedes-Benz Group saw a decline today as the luxury car maker announced a decrease in third-quarter profit. The drop in profit was attributed to lower demand and currency effects, and the company has cautioned that these challenges are expected to persist throughout the rest of the year.

At 7:26 AM GMT, shares in Mercedes-Benz were down 5.8%, trading at EUR57.82.

Factors Impacting Performance

Mercedes-Benz pointed to several factors influencing their financial performance. High supply-chain costs, inflation, and currency-exchange rates have all contributed to the decline. During a post-earnings call, Chief Financial Officer Harald Wilhelm expressed his expectation that these headwinds will persist into the fourth quarter.

Financial Figures

In the third quarter, net profit amounted to 3.72 billion euros ($3.93 billion), marking a 7% decrease compared to the same period last year. Revenue also experienced a decline of 1.4%, reaching EUR37.20 billion. Additionally, the return on sales for the cars business dropped from 14.5% to 12.4% year-on-year.

Sales Performance

Car sales saw a decline of 3.7%, contrasting with a 1.1% increase in van sales.

While facing ongoing challenges, Mercedes-Benz Group remains committed to navigating the current market conditions and ensuring the long-term success of their luxury car brand.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

3 + 3 =